Related Experiment Videos
Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma
Richard F. Little1, Wyndham H. Wilson
1*HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 10S255, 10 Center Drive MSC 1868, Bethesda, MD 20892-1868, USA. rlittle@helix.nih.gov
Abstract:
AIDS-related non-Hodgkin's lymphoma (ARL) is an opportunistic malignancy that foreshortens life more than any other commonly occurring HIV-associated cancer. Treatment strategies include low-dose chemotherapy, chemotherapy given with antiretroviral therapy, and infusional chemotherapy regimens. Rituximab, an anti-CD20 monoclonal antibody, has been found to be useful in non-HIV-associated lymphomas and is of interest in ARL as well. Since the advent of highly active antiretroviral therapy, the ARL incidence and survival has changed. This paper reviews the epidemiologic, biologic, and clinical features of ARL with the aim of presenting a cohesive overview of these elements.